TGFB1 and neoplasm: Therefore, combination therapies involving multiple ICIs or CAF inhibitors (e.g., TGF‐β inhibitors + anti‐PD‐1) may be more effective by counteracting the sustained immunosuppression and enhancing therapeutic outcomes for patients with KC3 subtype tumours.